New drug aims to rebuild immune defenses in brain cancer patients
NCT ID NCT03687957
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests an experimental drug called rhIL-7-hyFc in people with high-grade glioma, a type of brain cancer. The goal is to see if the drug can safely increase the number of infection-fighting white blood cells (lymphocytes) that often drop after standard radiation and chemotherapy. About 42 participants will receive either the drug or a placebo to measure its effect on their immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.